Thomas Weiser, Nicola Wilson: Inhibition of Tetrodotoxin (TTX)-Resistant and TTX-Sensitive Neuronal Na+ Channels by the Secretolytic Ambroxol. In: Molecular Pharmacology. Band62, Nr.3, 1. September 2002, S.433–438, doi:10.1124/mol.62.3.433, PMID 12181417 (aspetjournals.org [abgerufen am 27. Oktober 2019]).
doi.org
J. Germouty, J. L. Jirou-Najou: Clinical Efficacy of Ambroxol in the Treatment of Bronchial Stasis. Clinical Trial in 120 Patients at Two Different Doses. In: Respiration. Band51, Suppl. 1, 1987, S.37–41, doi:10.1159/000195273, PMID 3299566 (karger.com [abgerufen am 27. Oktober 2019]).
M. Post, J. J. Batenburg, E. A. J. M. Schuurmans, V. Oldenborg, A. J. van der Molen: The perfused rat lung as a model for studies on the formation of surfactant and the effect of Ambroxol on this process. In: Lung. Band161, Nr.1, Dezember 1983, S.349–359, doi:10.1007/BF02713884.
Marie-Claude Prevost, Georges Soula, Louis Douste-Blazy: Biochemical Modifications of Pulmonary Surfactant after Bromhexine Derivate Injection. In: Respiration. Band37, Nr.4, 1979, S.215–219, doi:10.1159/000194030 (karger.com [abgerufen am 27. Oktober 2019]).
M. F. Heath, W. Jacobson: The inhibition of lysosomal phospholipase A from rabbit lung by ambroxol and its consequences for pulmonary surfactant. In: Lung. Band163, Nr.1, 1. Dezember 1985, S.337–344, doi:10.1007/BF02713834.
Zenglin Liao, Jiajia Dong, Wei Wu, Ting Yang, Tao Wang: Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway. In: Respiratory Research. Band13, Nr.1, 2012, S.110, doi:10.1186/1465-9921-13-110, PMID 23199346, PMC 3545883 (freier Volltext).
Mario Malerba, Beatrice Ragnoli: Ambroxol in the 21st century: pharmacological and clinical update. In: Expert Opinion on Drug Metabolism & Toxicology. Band4, Nr.8, 1. August 2008, S.1119–1129, doi:10.1517/17425255.4.8.1119, PMID 18680446.
A. Gillissen, A. Bartling, S. Schoen, G. Schultze-Werninghaus: Antioxidant Function of Ambroxol in Mononuclear and Polymorphonuclear Cells in Vitro. In: Lung. Band175, Nr.4, 1. Juli 1997, S.235–242, doi:10.1007/PL00007570.
A. Gillissen, D. Nowak: Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. In: Respiratory Medicine. Band92, Nr.4, 1. April 1998, S.609–623, doi:10.1016/S0954-6111(98)90506-6.
Adrian Gillissen, Birgit Schärling, Małgorzata Jaworska, Almut Bartling, Kurt Rasche: Oxidant scavenger function of ambroxol in vitro: a comparison withN-acetylcysteine. In: Research in Experimental Medicine. Band196, Nr.1, 1. Dezember 1996, S.389–398, doi:10.1007/BF02576864.
K. Nobata, M. Fujimura, Y. Ishiura, S. Myou, S. Nakao: Ambroxol for the prevention of acute upper respiratory disease. In: Clinical and Experimental Medicine. Band6, Nr.2, 1. Juni 2006, S.79–83, doi:10.1007/s10238-006-0099-2.
Giorgio Fois, Nina Hobi, Edward Felder, Andreas Ziegler, Pika Miklavc: A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca2+ release from acidic Ca2+ stores. In: Cell Calcium. Band58, Nr.6, Dezember 2015, S.628–637, doi:10.1016/j.ceca.2015.10.002 (elsevier.com [abgerufen am 27. Oktober 2019]).
Alisdair McNeill, Joana Magalhaes, Chengguo Shen, Kai-Yin Chau, Derralyn Hughes, Atul Mehta, Tom Foltynie, J. Mark Cooper, Andrey Y. Abramov, Matthew Gegg, Anthony H. V. Schapira: Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. In: Brain. Band137, Nr.5, Mai 2014, S.1481–1495, doi:10.1093/brain/awu020.
Thomas Weiser, Nicola Wilson: Inhibition of Tetrodotoxin (TTX)-Resistant and TTX-Sensitive Neuronal Na+ Channels by the Secretolytic Ambroxol. In: Molecular Pharmacology. Band62, Nr.3, 1. September 2002, S.433–438, doi:10.1124/mol.62.3.433, PMID 12181417 (aspetjournals.org [abgerufen am 27. Oktober 2019]).
Andreas Leffler, Jennifer Reckzeh, Carla Nau: Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. In: European Journal of Pharmacology. Band630, Nr.1, 25. März 2010, S.19–28, doi:10.1016/j.ejphar.2009.12.027.
Jürgen Fischer, Uwe Pschorn, Jean-Michel Vix, Hubertus Peil, Bernhard Aicher: Efficacy and Tolerability of Ambroxol Hydrochloride Lozenges in Sore Throat. In: Arzneimittelforschung. Band52, Nr.4, April 2002, S.256–263, doi:10.1055/s-0031-1299889.
Alexander Schutz, Hans-Jürgen Gund, Uwe Pschorn, Bernhard Aicher, Hubertus Peil: Local Anaesthetic Properties of Ambroxol Hydrochloride Lozenges in View of Sore Throat. In: Arzneimittelforschung. Band52, Nr.3, März 2002, S.194–199, doi:10.1055/s-0031-1299879.
Justus Liebigs Annalen der Chemie 707, 107 (1967); J.Keck; Synthese der Metaboliten von Bisolvon; doi:10.1002/jlac.19677070117; Chem. Abstr. 1967:508342.
Giorgio Fois, Nina Hobi, Edward Felder, Andreas Ziegler, Pika Miklavc: A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca2+ release from acidic Ca2+ stores. In: Cell Calcium. Band58, Nr.6, Dezember 2015, S.628–637, doi:10.1016/j.ceca.2015.10.002 (elsevier.com [abgerufen am 27. Oktober 2019]).
J. Germouty, J. L. Jirou-Najou: Clinical Efficacy of Ambroxol in the Treatment of Bronchial Stasis. Clinical Trial in 120 Patients at Two Different Doses. In: Respiration. Band51, Suppl. 1, 1987, S.37–41, doi:10.1159/000195273, PMID 3299566 (karger.com [abgerufen am 27. Oktober 2019]).
Marie-Claude Prevost, Georges Soula, Louis Douste-Blazy: Biochemical Modifications of Pulmonary Surfactant after Bromhexine Derivate Injection. In: Respiration. Band37, Nr.4, 1979, S.215–219, doi:10.1159/000194030 (karger.com [abgerufen am 27. Oktober 2019]).
J. Germouty, J. L. Jirou-Najou: Clinical Efficacy of Ambroxol in the Treatment of Bronchial Stasis. Clinical Trial in 120 Patients at Two Different Doses. In: Respiration. Band51, Suppl. 1, 1987, S.37–41, doi:10.1159/000195273, PMID 3299566 (karger.com [abgerufen am 27. Oktober 2019]).
C. H. Ericsson, J. Juhász, E. Jönsson, B. Mossberg: Ambroxol therapy in simple chronic bronchitis: effects on subjective symptoms and ventilatory function. In: European Journal of Respiratory Diseases. Band69, Nr.4, Oktober 1986, S.248–255, PMID 3545883.
Zenglin Liao, Jiajia Dong, Wei Wu, Ting Yang, Tao Wang: Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway. In: Respiratory Research. Band13, Nr.1, 2012, S.110, doi:10.1186/1465-9921-13-110, PMID 23199346, PMC 3545883 (freier Volltext).
Mario Malerba, Beatrice Ragnoli: Ambroxol in the 21st century: pharmacological and clinical update. In: Expert Opinion on Drug Metabolism & Toxicology. Band4, Nr.8, 1. August 2008, S.1119–1129, doi:10.1517/17425255.4.8.1119, PMID 18680446.
K. M. Beeh, J. Beier, A. Esperester, L. D. Paul: Antiinflammatory properties of ambroxol. In: European Journal of Medical Research. Band13, Nr.12, 3. Dezember 2008, S.557–562, PMID 19073395.
Thomas Weiser, Nicola Wilson: Inhibition of Tetrodotoxin (TTX)-Resistant and TTX-Sensitive Neuronal Na+ Channels by the Secretolytic Ambroxol. In: Molecular Pharmacology. Band62, Nr.3, 1. September 2002, S.433–438, doi:10.1124/mol.62.3.433, PMID 12181417 (aspetjournals.org [abgerufen am 27. Oktober 2019]).
